Harnessing immune checkpoints for cancer therapy

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) modulate T-cell function to combat cancer.
• Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) are key inhibitory checkpoints.
• ICIs have demonstrated therapeutic efficacy across various tumor types.

Purpose of the Study:

• To review the current status of immune checkpoint inhibitors in cancer treatment.
• To discuss the side effects associated with these therapies.
• To explore future directions and potential of novel immune checkpoint targets.

Main Methods:

• Review of preclinical studies and clinical trial data on immune checkpoint inhibitors.
• Analysis of T-cell surface molecules as targets for cancer immunotherapy.
• Discussion of clinical outcomes and adverse events.

Main Results:

• CTLA-4 and PD-1/PD-L1 inhibitors have entered clinical practice with positive impacts on cancer remission.
• Targeting other T-cell surface molecules, including positive and negative regulators, shows significant antitumor activity.
• Several novel targets are progressing through clinical trials.

Conclusions:

• Immune checkpoint inhibitors represent a significant advancement in cancer immunotherapy.
• Ongoing research into novel targets and combination therapies promises to expand their clinical utility.
• Understanding and managing side effects remain crucial for optimizing patient outcomes.